Bioautography and its scope in the field of natural product chemistry

Medicinal plants, vegetables and fruits are the sources of huge number of bioactive lead/scaffolds with therapeutic and nutraceutical importance. Bioautography is a means of target-directed isolation of active molecules on chromatogram. Organic solvents employed in chromatographic separation process can be completely removed before biological detection because these solvents cause inactivation of enzymes and/or death of living organisms. They offer a rapid and easy identification of bioactive lead/scaffolds in complex matrices of plant extracts. Bioautography is a technique to isolate hit（s）/lead（s） by employing a suitable chromatographic process followed by a biological detection system. This review critically describes the methodologies to identify antimicrobial, antioxidant, enzyme inhibitor lead/scaffolds by employing bioautography. A significant number of examples have been incorporated to authenticate the methodologies.

Differential physiological and biochemical responses under variable culture conditions in micro-propagated Solenostemon scutellarioides:an important ornamental plant

Solenostemon scutellarioides is a commercially important ornamental plant.In present study,it was attempted to establish a protocol for high frequency in vitro regeneration of S.scutellarioides.Caulogenesis was found to be significant in solid MS medium supplemented with 0.5 mg dm^(-3)BAP.Combination of GA3(0.5 mg dm^(-3))and BAP(0.5 mg dm^(-3))induced high frequency regeneration coupled with higher plant height.The plantlets exposed to IBA(1 mg dm^(-3))exhibited significant root development in terms of first appearance of root and number of roots per shoot.To improve its commercial acceptability in terms of plant architecture and foliage colouration,two weeks old in vitro grown plantlets were exposed to different culture conditions namely MS strength,sucrose concentration,pH and light.A variable plant types with diverse ornamental traits were developed under different culture conditions.

Corrigendum to'Cancer chemotherapy and beyond:Current status,drug candidates,associated risks and progress in targeted therapeutics'[Genes&Diseases 10(2023)1367-1401]

In the published article,there was an error in the affiliation information about the first author Uttpal Anand[a].Instead of"Department of Life Sciences,Ben-Gurion University of the Negev,Beer-Sheva 84105,Israel",it should be"CytoGene Research&Development LLP,K-51,UPSIDA Industrial Area,Kursi Road(Lucknow),Dist.Barabanki,225001,Uttar Pradesh,India".The authors would like to apologize for any inconvenience caused and state that this does not change the scientific conclusions of thearticle inanyway.

Non-small cell lung carcinoma(NSCLC):Implications on molecular pathology and advances in early diagnostics and therapeutics

Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance.

Cancer chemotherapy and beyond:Current status,drug candidates,associated risks and progress in targeted therapeutics

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year.With the new understanding of the molecular mechanism(s)of disease progression,our knowledge about the disease is snowballing,leading to the evolution of many new therapeutic regimes and their successive trials.In the past few decades,various combinations of therapies have been pro-posed and are presently employed in the treatment of diverse cancers.Targeted drug therapy,immunotherapy,and personalized medicines are now largely being employed,which were not common a few years back.The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies,extending patients’disease-free survival thereafter.Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine,chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient’s physical and psychological health.Chemother-apeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons.The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals;it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.